Evidence map›Paper›PMID 42435181›Full record

ReviewAdvances in experimental medicine and biology2026

Mitochondrial Energy Metabolism in Cancer, Immunoregulation and Antitumour Response.

João S Patrício, Cindy Mendes, Paulo A Gameiro

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

João S Patrício *iNOVA4Health, NOVA Medical School | Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Lisboa, Portugal.
Cindy Mendes *iNOVA4Health, NOVA Medical School | Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Lisboa, Portugal.
Paulo A GameiroiNOVA4Health, NOVA Medical School | Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Lisboa, Portugal. paulo.gameiro@nms.unl.pt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitochondria are the cells' powerhouse, a dogma that has guided research for decades. While this bioenergetic view is accurate, it fails to capture the extra-metabolic signalling functions of mitochondria, as well as the complexity of mitochondrial homeostasis and its contribution to disease pathogenesis, particularly in cancer. In this chapter, we review the multifaceted role of mitochondria in cancer and immunity, starting from the bioenergetic point of view and expanding to metabolic reprogramming in cancer, their role in signalling regulation, immune cell homeostasis and promising immunotherapeutic approaches to treat cancer. We highlight how metabolic flexibility, including the coordinated activation of glycolysis and oxidative phosphorylation (OxPhos), rewiring of the tricarboxylic acid (TCA) cycle, and regulation of redox balance, underpins tumour growth and immune evasion. Special attention is given to mitochondrial-derived signals, such as reactive oxygen species (ROS), lactate shuttling, and mitochondrial DNA (mtDNA) release, that modulate both innate and adaptive immune responses within the tumour microenvironment (TME). Moreover, we further elucidate mitochondrial energy metabolism as a pivotal cornerstone of both cancer prevention and treatment, emphasising its therapeutic potential in overcoming immune suppression and enhancing the efficacy of interventions such as immune checkpoint blockade, adoptive T-cell transfer, and natural killer cell-based therapies.

Indexed as

Energy MetabolismMitochondriaNeoplasmsAnimalsCitric Acid CycleHumansImmunotherapyMetabolic ReprogrammingOxidative PhosphorylationReactive Oxygen SpeciesSignal TransductionTumor MicroenvironmentReactive Oxygen SpeciesCancerImmunometabolismImmunotherapyMitochondrial metabolismReactive oxygen species (ROS)Tricarboxylic acid (TCA) cycle

Identifiers

PMID42435181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.